MDGL
Madrigal Pharmaceuticals, Inc.
$329.24
Earnings Summary
Revenue | $62.18Mn |
Net Profits | $-106.96Mn |
Net Profit Margins | -172.04% |
Highlights
Madrigal Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $62.18Mn in the Q3 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 324.75% jump in its revenue since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit fell -8.33% since last year same period to $-106.96Mn in the Q3 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 29.62% jump in its net profits since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -172.04% in the Q3 2024. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 83.43% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Madrigal Pharmaceuticals, Inc. post its latest quarter earnings
EPS Estimate Current Year | -6.28 |
Highlights
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.28.
Key Ratios
Key ratios of the Madrigal Pharmaceuticals, Inc. post its Q3 2024 earnings
Earning Per Share (EPS) | -4.92 |
Highlights
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 7.87% since last year same period to -4.92 in the Q3 2024. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 7.87% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-07 | -6.28 | -7.38 | -17.52% |
2024-08-07 | -7.53 | -7.1 | 5.71% |
2024-10-31 | -6.91 | -4.92 | 28.8% |
₹0 US Stocks a/c Opening Fee